NASDAQ:AHCO - AdaptHealth Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $40.11
  • Forecasted Upside: 56.68 %
  • Number of Analysts: 10
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$25.60
▼ -0.2 (-0.78%)

This chart shows the closing price for AHCO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AdaptHealth Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AHCO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AHCO

Analyst Price Target is $40.11
▲ +56.68% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for AdaptHealth in the last 3 months. The average price target is $40.11, with a high forecast of $50.00 and a low forecast of $30.00. The average price target represents a 56.68% upside from the last price of $25.60.

This chart shows the closing price for AHCO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 10 investment analysts is to buy stock in AdaptHealth. This rating has held steady since June 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
5/1/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
7/30/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 1 sell ratings
1/26/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 1 sell ratings
4/26/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 1 sell ratings
7/25/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 1 sell ratings
9/23/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 1 sell ratings
10/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/13/2021Truist SecuritiesLower Price TargetBuy$40.00 ➝ $30.00Low
10/13/2021TruistLower Price TargetBuy$40.00 ➝ $30.00Low
9/27/2021SVB LeerinkInitiated CoverageOutperform$30.00High
7/14/2021Robert W. BairdUpgradeNeutral ➝ Outperform$30.00 ➝ $36.00High
5/7/2021Canaccord GenuityBoost Price TargetBuy$44.00 ➝ $50.00High
5/7/2021Deutsche Bank AktiengesellschaftLower Price TargetHold ➝ Sell$47.00 ➝ $40.00High
4/19/2021Robert W. BairdReiterated RatingOutperform ➝ Neutral$35.00N/A
4/13/2021Robert W. BairdDowngradeOutperform ➝ Neutral$35.00High
4/12/2021Robert W. BairdBoost Price TargetPositive ➝ Outperform$47.00 ➝ $49.00Medium
3/18/2021Truist FinancialInitiated CoverageBuyHigh
3/18/2021Truist SecuritiesInitiated CoverageBuy$48.00High
3/18/2021TruistInitiated CoverageBuy$48.00High
1/26/2021Bank of AmericaInitiated CoverageBuy$46.00Medium
1/7/2021Canaccord GenuityBoost Price TargetFocus Stock ➝ Buy$39.00 ➝ $50.00Low
12/10/2020UBS GroupInitiated CoverageBuy$49.00High
12/4/2020Deutsche Bank AktiengesellschaftBoost Price TargetBuy$36.00 ➝ $47.00Low
12/2/2020Canaccord GenuityBoost Price TargetBuy$36.00 ➝ $39.00High
12/2/2020SVB LeerinkBoost Price TargetOutperform$32.50 ➝ $39.50Low
12/2/2020Royal Bank of CanadaBoost Price TargetPositive ➝ Outperform$36.00 ➝ $50.00Low
11/19/2020Canaccord GenuityBoost Price TargetBuy$34.00 ➝ $36.00Low
11/17/2020Deutsche Bank AktiengesellschaftBoost Price TargetBuy$26.00 ➝ $36.00Low
11/16/2020Robert W. BairdInitiated CoverageOutperform$35.00Low
11/5/2020Canaccord GenuityBoost Price TargetBuy$31.00 ➝ $34.00Medium
11/5/2020SVB LeerinkBoost Price TargetOutperform$23.50 ➝ $32.50Medium
8/11/2020Royal Bank of CanadaBoost Price TargetOutperform$24.00 ➝ $33.00Medium
8/10/2020Canaccord GenuityInitiated CoverageBuy$31.00Medium
8/6/2020Deutsche Bank AktiengesellschaftBoost Price Target$10.00 ➝ $26.00Low
7/1/2020SVB LeerinkInitiated CoverageOutperform$21.00High
6/9/2020Royal Bank of CanadaInitiated CoverageOutperform$24.00Medium
5/27/2020Stifel NicolausBoost Price TargetBuy$18.00 ➝ $20.00Low
2/28/2020Deutsche Bank AktiengesellschaftBoost Price TargetBuy$12.00 ➝ $19.00High
2/26/2020Stifel NicolausBoost Price TargetBuy$17.00 ➝ $18.00High
1/30/2020Stifel NicolausInitiated CoverageBuy$17.00Medium
1/7/2020Jefferies Financial GroupInitiated CoverageBuy$15.00High
12/9/2019Deutsche Bank AktiengesellschaftInitiated CoverageBuy$12.00High
(Data available from 10/24/2016 forward)

News Sentiment Rating

0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/28/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/27/2021
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/27/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/26/2021
  • 1 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
7/26/2021
  • 40 very positive mentions
  • 47 positive mentions
  • 31 negative mentions
  • 6 very negative mentions
8/25/2021
  • 6 very positive mentions
  • 25 positive mentions
  • 6 negative mentions
  • 2 very negative mentions
9/24/2021
  • 3 very positive mentions
  • 15 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
10/24/2021

Current Sentiment

  • 3 very positive mentions
  • 15 positive mentions
  • 4 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

AdaptHealth logo
AdaptHealth Corp. engages in the provision of home healthcare equipment, supplies and related services. It focuses on sleep therapy equipment to individuals suffering from obstructive sleep apnea (OSA), home medical equipment to patients discharged from acute care and other facilities, oxygen and related chronic therapy services in the home, and HME medical devices and supplies on behalf of chronically ill patients with diabetes care, wound care, urological, ostomy, and nutritional supply needs. The company was founded in 2012 and is headquartered in Plymouth Meeting, PA.
Read More

Today's Range

Now: $25.60
Low: $25.31
High: $25.88

50 Day Range

MA: $23.96
Low: $22.69
High: $25.38

52 Week Range

Now: $25.60
Low: $21.00
High: $41.58

Volume

314,036 shs

Average Volume

1,094,635 shs

Market Capitalization

$3.35 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of AdaptHealth?

The following equities research analysts have issued reports on AdaptHealth in the last twelve months: Bank of America Co., Canaccord Genuity, Deutsche Bank Aktiengesellschaft, Robert W. Baird, Royal Bank of Canada, SVB Leerink LLC, TheStreet, Truist, Truist Financial Co., Truist Securities, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for AHCO.

What is the current price target for AdaptHealth?

9 Wall Street analysts have set twelve-month price targets for AdaptHealth in the last year. Their average twelve-month price target is $40.11, suggesting a possible upside of 56.7%. Canaccord Genuity has the highest price target set, predicting AHCO will reach $50.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $30.00 for AdaptHealth in the next year.
View the latest price targets for AHCO.

What is the current consensus analyst rating for AdaptHealth?

AdaptHealth currently has 1 sell rating and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AHCO will outperform the market and that investors should add to their positions of AdaptHealth.
View the latest ratings for AHCO.

What other companies compete with AdaptHealth?

How do I contact AdaptHealth's investor relations team?

AdaptHealth's physical mailing address is 220 West Germantown Pike Suite 250, Plymouth Meeting PA, 19462. The company's listed phone number is (610) 630-6357 and its investor relations email address is [email protected] The official website for AdaptHealth is www.adapthealth.com.